While Skye Bioscience Inc has underperformed by -1.08%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SKYE fell by -67.49%, with highs and lows ranging from $5.75 to $0.93, whereas the simple moving average fell by -62.85% in the last 200 days.
On October 06, 2025, Craig Hallum Downgraded Skye Bioscience Inc (NASDAQ: SKYE) to Hold. A report published by Cantor Fitzgerald on October 06, 2025, Downgraded its rating to ‘Neutral’ for SKYE. Evercore ISI also rated SKYE shares as ‘Outperform’, setting a target price of $10 on the company’s shares in an initiating report dated August 15, 2025. Scotiabank initiated its ‘Sector Outperform’ rating for SKYE, as published in its report on September 30, 2024. JMP Securities’s report from September 10, 2024 suggests a price prediction of $15 for SKYE shares, giving the stock a ‘Mkt Outperform’ rating. Craig Hallum also rated the stock as ‘Buy’.
Analysis of Skye Bioscience Inc (SKYE)
To gain a thorough understanding of Skye Bioscience Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -94.31% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.77, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and SKYE is recording an average volume of 816.54K. On a monthly basis, the volatility of the stock is set at 9.31%, whereas on a weekly basis, it is put at 14.32%, with a loss of -14.81% over the past seven days. Furthermore, long-term investors anticipate a median target price of $8.25, showing growth from the present price of $0.92, which can serve as yet another indication of whether SKYE is worth investing in or should be passed over.
How Do You Analyze Skye Bioscience Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 37.98%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 25.59% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
